Skip To Main Content
For US Healthcare Professionals

What is ENSPRYNG?

Meet the only subcutaneous self-injectable* NMOSD treatment proven to reduce risk of relapse† for adults who are AQP4+ and backed by an established safety profile.‡

*After doctor approval & training
†ENSPRYNG alone compared to placebo in Study 1. ENSPRYNG plus IST compared to placebo plus IST In Study 2.
‡ENSPRYNG may cause serious side effects including: infections, increased liver enzymes, and low neutrophil counts. All required vaccinations should be completed before starting ENSPRYNG. Do not take ENSPRYNG If you are allergic to satralizumab-mwge or any of the ingredients in ENSPRYNG, have an active hepatitis B infection. or have active or untreated inactive (latent) TB.

Print Page
ENSPRYNG patient Cheena, diagnosed with NMOSD in 2021

Say hello to a different kind of treatment

ENSPRYNG is the first and only approved NMOSD treatment designed to block the action of interleukin 6 (IL-6)—a protein that may play an important role in NMOSD.

The exact way ENSPRYNG works is not fully known.

ENSPRYNG mechanism of action

WITHOUT ENSPRYNG

IL-6 connects to the cell surface and activates the cell.

ENSPRYNG red arrow
ENSPRYNG mechanism of action

WITH ENSPRYNG

ENSPRYNG blocks IL-6 from connecting to the cell surface and prevents the activation of the cell.

Why ENSPRYNG might be right for you

ENSPRYNG safety icon

ENSPRYNG is proven effective in reducing the risk of relapse for adults with AQP4+ NMOSD and has an established safety profile

ENSPRYNG clinical studies icon

ENSPRYNG reduced the risk of relapse in 2 clinical studies, across a diverse group of patients from many countries

ENSPRYNG self inect icon

ENSPRYNG is the only monthly* self-injection treatment for NMOSD given under the skin with your doctor's approval and training

*ENSPRYNG is given every 4 weeks after taking 3 starter doses in your first month of treatment.

Consider ENSPRYNG if you are:

  • Newly diagnosed and receiving NMOSD treatment
  • Currently treating with oral immunosuppressive therapies (ISTs) such as azathioprine, mycophenolate mofetil, or oral corticosteroids
  • Uncertain with or not responding well to current therapy

Sign up for information and support

Receive information about ENSPRYNG and the support options available to you

Go to Sign Up
NEXT: Clinical Trials

Important Safety Information & Indication

What is ENSPRYNG?

ENSPRYNG is a prescription medicine used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are aquaporin-4 (AQP4) antibody positive. It is not known if ENSPRYNG is safe and effective in children.

Who should not receive ENSPRYNG?

Do not take ENSPRYNG if you:

  • are allergic to ENSPRYNG or any of the ingredients in ENSPRYNG.
  • have an active hepatitis B infection.
  • have active or untreated inactive (latent) tuberculosis.
What is the most important information I should know about ENSPRYNG?

ENSPRYNG may cause serious side effects including:

  • Infections. ENSPRYNG can increase your risk of serious infections, some of which can be life-threatening. Talk to your healthcare provider if you are being treated for an infection, or call them right away if you think you have signs of an infection, with or without a fever, such as:
    • chills, feeling tired, muscle aches, cough that will not go away or a sore throat
    • skin redness, swelling, tenderness, pain or sores on your body
    • diarrhea, belly pain, or feeling sick
    • burning when you urinate or urinating more often than usual

Your healthcare provider will check if you have an infection and treat it if needed before you start or continue to take ENSPRYNG.

  • Your healthcare provider should test you for hepatitis and tuberculosis (TB) before you start taking ENSPRYNG.
  • All required vaccinations should be completed before starting ENSPRYNG. People using ENSPRYNG should not be given ‘live’ or ‘live-attenuated’ vaccines. ‘Live’ or ‘live-attenuated’ vaccines should be given at least 4 weeks before you start ENSPRYNG. Your healthcare provider may recommend that you get a ‘non-live’ (inactivated) vaccine, such as some of the seasonal flu vaccines. If you plan to get a ‘non-live’ (inactivated) vaccine, it should be given, whenever possible, at least 2 weeks before you start ENSPRYNG.
  • Increased liver enzymes.
    Your healthcare provider should order blood tests to check your liver enzymes before and while you are taking ENSPRYNG. Your healthcare provider will tell you how often you will need to have these blood tests. Make sure you get all of your follow-up blood tests as ordered by your healthcare provider. Your healthcare provider will tell you if you need to wait to start ENSPRYNG if your liver enzymes are increased.
  • Low neutrophil count.
    ENSPRYNG can cause a decrease in your neutrophil counts in your blood. Neutrophils are white blood cells that help the body fight off bacterial infections. Your healthcare provider should order blood tests to check your neutrophil count while you are taking ENSPRYNG.
  • Serious allergic reactions.
    Serious allergic reactions that may be life-threatening have happened with other medicines like ENSPRYNG. Tell your healthcare provider before taking your next dose if you had hives, rash, or flushing after your injection. Seek medical attention right away if you have any symptoms of a serious allergic reaction, such as:
    • shortness of breath or trouble breathing
    • dizziness or feeling faint
    • swelling of your lips, face, or tongue
    • moderate or severe stomach (abdominal) pain or vomiting
    • chest pain    

Before you take ENSPRYNG, tell your healthcare provider about all of your medical conditions, including if you:

  • have or think you have an infection. See "What is the most important information I should know about ENSPRYNG?"
  • have liver problems.
  • have ever had hepatitis B or are a carrier of the hepatitis B virus.
  • have had or have been in contact with someone with tuberculosis.
  • have had a recent vaccination or are scheduled to receive any vaccination.
  • are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if ENSPRYNG will harm your unborn baby.
    • Pregnancy Registry: There is a registry for pregnant women who take ENSPRYNG. The purpose of this registry is to check the health of the pregnant mother and her baby. If you are pregnant or become pregnant while taking ENSPRYNG, talk to your healthcare provider about how you can join this pregnancy registry, or you may contact the registry at 1-833-277-9338 to enroll.
  • are breastfeeding or plan to breastfeed. It is not known if ENSPRYNG passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take ENSPRYNG.

Tell your healthcare provider about all the medicines you are taking, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the most common side effects of ENSPRYNG?
The most common side effects of ENSPRYNG include:

  • sore throat, runny nose (nasopharyngitis)
  • rash
  • fatigue
  • extremity pain
  • headache
  • upper respiratory tract infection
  • nausea
  • inflammation of the stomach lining (gastritis)
  • joint pain (arthralgia)

These are not all the possible side effects of ENSPRYNG.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555.

For more information, call 1-844-NSPRYNG.

For additional safety information, please see the full Prescribing Information and Medication Guide.

TOP